V I S I T
WORLD’S CLINICAL LABORATORY NEWS LEADER ISSN 1068-1760
I
N
Vol.41 No.3 • 5/2024
T
AI Technique Advances Colorectal Diagnostics
T
he incidence and mortality rates of colorectal cancer (CRC) are on an alarming rise, with predictions showing a continuous increase until at least 2040. Currently, CRC ranks as the third most diagnosed (10.7% of all cancer cases) and the sec-
Cont’d on page 6
E
R
N
A
T
I
DAILY CLINICAL LAB NEWS
®
O
Innovative Platform Provides Antibiotic Susceptibility Testing with Unprecedented Speed
A
groundbreaking diagnostic platform that delivers antibiotic susceptibility test (AST) results with unprecedented speed can become an important tool for healthcare professionals to manage bacteremia. The LifeScale AST system from
Affinity Biosensors (Santa Barbara, CA, USA; affinitybio.com) is a state-of-the-art diagnostic platform that rapidly identifies the most effective antibiotics for treating dangerous bloodstream infections. This revolutionary system enables healthcare professionals Cont’d on page 13
Genetic Testing Combined with Drug Screening of Tumors Could Transform Cancer Treatment
See article on page 12
V
I
S
I
T
LINKXPRESS COM
R E A D E R
S E R V I C E
®
P O R T A L
Renew/Start your Free Subscription Access Interactive Digital Magazine Instant Online Product Information: Identify LinkXpress ® codes of 1 interest as you read magazine on LinkXpress.com 2 toClick reach reader service portal Mark code(s) of interest on 3 LinkXpress ® inquiry matrix
If your subscription is not renewed every 12 months your Free Subscription may be automatically discontinued
A
L
New Device Overcomes Phlebotomy Problems
T
he discomfort associated with traditional blood draws leads to a significant issue: approximately 30% of diagnostic tests prescribed by physicians are never completed by patients. This avoidance is often due to the fear of pain from needle sticks and a reluctance to visit medical facilities where there’s a perceived risk of encountering illness. Now, a virtually pain-free, low-cost, Cont’d on page 5
Blood Test Improves Sepsis Diagnosis
C
urrent genomic profiling can analyze thousands of genes but still fail to indicate a clear treatment path. Now, for the first time, researchers have combined genetic testing with personalized drug screening of tumor samples, identifying the right cancer therapy.
N
S
epsis, a critical condition that arises from organ dysfunction due to severe infection, can progress to severe sepsis and septic shock, leading to multi-organ failure and increased mortality rates. The complexity of diagnosing sepsis stems from the absence of a definitive test, with current detection methods depending on broad-ranged biomarkers such as CRP, PCT, and lactate levels.
Image: Embryonic stem cells in cellular therapy (Shutterstock)
Cont’d on page 10
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
H
emoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations ranges from
P
LabMedica EXPO . 6-20
Clinical News . . . . 2-20
IFCC News . . . . 17-19 Cont’d on page 8
Groundbreaking Blood Test Offers Earlier Pancreatic Cancer Diagnosis
ancreatic cancer ranks as the third leading cause of cancer-related deaths, primarily due to its late detection. Early discovery of the disease, while it’s still treatable, could significantly impact survival rates. For more than a century, scientists have
INSIDE
sought to link cancer with cellular energy production and metabolism. The advent of quantitative mass spectrometry has enabled the testing of many such theories. Now, for the first time, researchers have utilized targeted mass spectrometry to demonstrate that Cont’d on page 14
Industry News .. . . . 21 Events Calendar . . 22
PUBLISHED IN COOPERATION WITH
International Federation of Clinical Chemistry and Laboratory Medicine
GLOBETECH >>> MEDIA <<<